Liu Jian-Yong, Zhang Chun-Yan, Zhao Yin-Nong, Tang Kai, Zhang Li-Tu, Li Ting
Department of Surgery, Affiliated Cancer Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, PR China.
Ai Zheng. 2003 Oct;22(10):1030-3.
BACKGROUND & OBJECTIVE: Dendritic cell (DC) is the strongest antigen presenting cell(APC). It can present antigen to T lymphocytes in vivo and in vitro,and induce cytotoxic T lymphocyte(CTL) reactions.This study was designed to investigate the killing activity of tumor infiltrating lymphocytes (TILs) stimulated by dendritic cells on breast cancer cells in vitro.
DCs were isolated from peripheral blood of patients with breast cancer. DCs were stimulated by granulocyte/macrophage colony stimulating factor (GM-CSF), interleukin-4(IL-4), and tumor antigen. Then TILs were stimulated by DCs and their killing activity on autogenous breast cancer cells and Bcap-37 breast cancer cells in vitro were observed.
TILs stimulated by DCs had very high killing activity on autogenous breast cancer cells and the killing rate was (85.76+/-2.93)%. The killing rate was higher obviously than that of TILs not stimulated by DCs and T lymphocytes stimulated by DCs or not on autogenous breast cancer cells, respectively [killing rates: (52.11+/-1.48)%, (51.35+/-1.46)%, and (3.59+/-0.25)%, respectively]. However, their killing activities on Bcap-37 breast cancer cells were lower [killing rates: (40.03+/-1.29)%, (22.09+/-0.87)%, (21.66+/-0.85)%, and (1.76+/-0.14)%, respectively].
The results indicate that DC from the patients with breast cancer can induce TIL to produce efficient and specific anti-breast cancer immune response.
树突状细胞(DC)是最强的抗原呈递细胞(APC)。它能在体内外将抗原呈递给T淋巴细胞,并诱导细胞毒性T淋巴细胞(CTL)反应。本研究旨在体外研究树突状细胞刺激的肿瘤浸润淋巴细胞(TILs)对乳腺癌细胞的杀伤活性。
从乳腺癌患者外周血中分离DC。用粒细胞/巨噬细胞集落刺激因子(GM-CSF)、白细胞介素-4(IL-4)和肿瘤抗原刺激DC。然后用DC刺激TILs,并观察其体外对自体乳腺癌细胞和Bcap-37乳腺癌细胞的杀伤活性。
DC刺激的TILs对自体乳腺癌细胞具有很高的杀伤活性,杀伤率为(85.76±2.93)%。该杀伤率明显高于未用DC刺激的TILs以及分别用或未用DC刺激的T淋巴细胞对自体乳腺癌细胞的杀伤率[杀伤率分别为:(52.11±1.48)%、(51.35±1.46)%和(3.59±0.25)%]。然而,它们对Bcap-37乳腺癌细胞的杀伤活性较低[杀伤率分别为:(40.03±1.29)%、(22.09±0.87)%、(21.66±0.85)%和(1.76±0.14)%]。
结果表明,乳腺癌患者的DC可诱导TIL产生高效、特异的抗乳腺癌免疫反应。